Xiaodong X Cheng

US Patent:

20070178523, Aug 2, 2007

Filed:

Aug 6, 2003

Appl. No.:

10/636508

Inventors:

Xiaodong Cheng - Decatur GA, US
Xing Zhang - Decatur GA, US

Assignee:

Emory University - Atlanta GA

International Classification:

C40B 30/02
C40B 30/06
C40B 40/10

US Classification:

435007100, 514012000, 702019000

Abstract:

The present invention relates to novel druggable regions discovered in histone H3 lysine methyltransferase DIM-5, which is a SET domain protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases in which the activity of SET domain proteins are implicated, for example, anti-cancer/anti-proliferative agents or anti-fungal agents.

US Patent:

20070243547, Oct 18, 2007

Filed:

Feb 13, 2007

Appl. No.:

11/706109

Inventors:

Xiaodong Cheng - League City TX, US
Fang Mel - League City TX, US
Travis Young - Galveston TX, US
Jinsong Liu - Houston TX, US

International Classification:

A61K 31/7088
A61P 35/00
C12Q 1/68

US Classification:

435006000, 514044000

Abstract:

The present invention discloses the link between oncogenic Ras and TSG101 and the negative effect of TSG101 on the expression of p21 in ovarian cancer. The present also discloses the use of TSG101 as a prognostic, diagnostic marker and a potential therapeutic target in cancer, especially ovarian cancer.

US Patent:

20100035945, Feb 11, 2010

Filed:

Dec 6, 2005

Appl. No.:

11/720971

Inventors:

Xiaodong Cheng - Decatur GA, US
John R. Horton - Stone Mountain GA, US
Zhe Yang - Atlanta GA, US
Daniel Kalman - Atlanta GA, US
Xing Zhang - Decatur GA, US
Stanley Hattman - Rochester NY, US
Albert Jeltsch - Ritterhude, DE

International Classification:

A61K 31/427
G06G 7/60
C12N 9/10
A61P 31/04

US Classification:

514370, 703 11, 435193

Abstract:

Disclosed are compounds, crystal structures, data representations, methods of using, and methods of identifying compounds in relation to DNA methylation and inhibition of methylation. In embodiments, DNA methylation is by DNA-adenine methyltransferases (Dam). In an embodiment, compounds are used to treat a host suspected of infection by a pathogenic organism. In an embodiment, virulence of a pathogenic bacterium is modified by treatment with an agent capable of inhibiting a bacterial Dam enzyme. In an embodiment, compounds and methods are disclosed regarding Dam inhibitors.

US Patent:

20160263088, Sep 15, 2016

Filed:

Mar 10, 2016

Appl. No.:

15/066416

Inventors:

Xiaodong Cheng - Houston TX, US
Fang Mei - Houston TX, US
Annemieke Kavelaars - Houston TX, US
Cobi J. Heijnen - Houston TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 31/42

Abstract:

Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.

US Patent:

20140348853, Nov 27, 2014

Filed:

Aug 8, 2014

Appl. No.:

14/455325

Inventors:

Bin Gong - League City TX, US
Xiaodong Cheng - League City TX, US
David Walker - Galveston TX, US
Fang Mei - League City TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 31/42
A61K 45/06

US Classification:

4241531, 514378, 4241841

Abstract:

Embodiments of the invention are directed to compounds that inhibit an activity of EPAC proteins and methods of using the same.

US Patent:

20140294764, Oct 2, 2014

Filed:

Nov 8, 2012

Appl. No.:

14/356024

Inventors:

Young-Sup Yoon - Atlanta GA, US
Xiaodong Cheng - Decatur GA, US
Ji Woong Han - Decatur GA, US
Antonello Mai - Rome, IT

Assignee:

ISTITUTO PASTEUR - FONDAZIONE CENCI BOLOGNETTI - Rome
EMORY UNIVERSITY - Atlanta GA

International Classification:

C07D 401/12
A61K 31/551
A61K 45/06
A61K 31/541
A61K 31/55
C07D 401/14
A61K 31/517
A61K 31/5377

US Classification:

424 852, 544291, 51425217, 540575, 514218, 544119, 5142345, 544 62, 5142282, 540600, 51421706, 51426622, 514 43, 514 91, 514 89

Abstract:

This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.